Patients in focus: Diaverum at ERA/EDTA 2015 in London

Report this content

Renal care provider presents science and service portfolio at European congress

Munich / London, 27 May 2015 – Diaverum, one of the world’s leading renal care providers, is presenting its service portfolio and the results of its latest research at the ERA/EDTA 2015 in London. The studies showcase the strong focus on the physical and emotional well-being of renal patients.

“The ERA/EDTA is the most important nephrology congress in Europe giving insights into current trends in renal care. On our path to integrated care it is essential for us as a global player to meet with international healthcare companies and the best physicians worldwide in London”, said Dag Andersson, CEO and President of Diaverum.

“To improve quality of life for renal patients we are placing a strong emphasis on their complex needs in our scientific research”, explained Prof. Giovanni Strippoli, Senior Vice President Scientific Affairs at Diaverum and Chairman of the Diaverum Academy. “We will present four posters at ERA/EDTA in London: The studies look at the prevalence of periodontal and early mortality as well as depression and sexual dysfunction in patients undergoing haemodialysis treatments.”

Posters

Diaverum will present four posters at the ERA/EDTA 2015:

  • Pharmacological interventions for depression in adults with end-stage kidney disease, Friday, May 29 2015 (no FP706)
  • Periodontitis and early mortality in adults with kidney failure treated with hemodialysis: A multinational observational study, Saturday, May 30 2015 (no SP748)
  • Domains of sexual dysfunction in women with ends-stage kidney disease treated with hemodialysis: A multinational cross sectional study, Saturday, May 30 2015 (no SP722)
  • Depressive symptoms and early all−cause and cardiovascular mortality in hemodialysis patients: a multinational cohort study, Saturday, May 30 2015 (no SP701)

Exhibition

At the Diaverum booth, situated in hall S17 – S21 in the ExCel congress centre in London (no E40) visitors can learn more about Diaverum and meet the renal care experts.

The exhibition starts on Thursday, 28 May at 19.00pm CET, and ends on Sunday, 31 May, 14.30pm. Visitors are welcome to learn more about Diaverum and to meet the Diaverum experts and the top management team.

Press Contact

Ulrike Beringer

Corporate Communications Diaverum

E-mail: Ulrike.Beringer@diaverum.com

Phone: 49 89 45 2444 124


About Diaverum

At Diaverum, our mission is to improve the quality of life for renal patients by revitalising them both physically and emotionally. Being one of the world’s leading renal care providers, Diaverum offers a holistic approach, from preventive and early stage renal care to all renal replacement therapies. As a product independent provider — the largest in Europe — we are able to focus solely on caring for the individual needs of our patients. Our experience in renal care dates back 20 years, when the first dialysis clinic was established, previously under our former name Gambro Healthcare. Today, 8,500 employees care for 26,000 patients in 20 countries in Europe, Latin America, Middle East/Asia and Australia/New Zealand. Diaverum has its roots in Lund, Sweden and a corporate office located in Munich, Germany.

Tags:

Subscribe

Quick facts

The exhibition starts on Thursday, 28 May at 19.00pm CET, and ends on Sunday, 31 May, 14.30pm. Visitors are welcome to learn more about Diaverum and to meet the Diaverum experts and the top management team.
Tweet this

Quotes

“The ERA/EDTA is the most important nephrology congress in Europe giving insights into current trends in renal care. On our path to integrated care it is essential for us as a global player to meet with international healthcare companies and the best physicians worldwide in London.”
Dag Andersson, CEO and President of Diaverum
“To improve quality of life for renal patients we are placing a strong emphasis on their complex needs in our scientific research. We will present four posters at ERA/EDTA in London: The studies look at the prevalence of periodontal and early mortality as well as depression and sexual dysfunction in patients undergoing haemodialysis treatments.”
Prof. Giovanni Strippoli, Senior Vice President Scientific Affairs at Diaverum and Chairman of the Diaverum Academy.